We are thrilled to announce our collaboration between Enamine and ChemPass, which will open the way for significant advancements in drug discovery. ChemPass will apply its cutting-edge approach to design innovative fragment libraries, and Enamine ensures that these novel compounds are synthesized efficiently. Together, we are establishing a new standard for fragment-screening libraries that will enable scientists to do research more quickly and effectively.
The joint effort between the two companies aims to significantly expand fragment-based hit discovery and to shorten the fragment-to-lead development cycle for challenging biological targets.
ChemPass, applying its Universal Fragment Library Design Platform, will provide general or target-specific fragment libraries based on the customer’s biological target of interest.
Enamine’s team will support the screening of the fragment libraries, the expansion of the obtained fragment hits into lead-like analogues from Enamine REAL® Space, the development of structure-activity relationship (SAR) by a few rapid rounds of screening of REAL® catalog compounds.
Overall, the application of the ChemPass Library Design Platform, Enamine’s REAL® combined with its extensive medicinal chemistry expertise, and Enamine’s screening facilities in discovery biology will deliver optimized hits to our clients in five months, a true acceleration of early-phase drug discovery.
Why UFrag™ library from Enamine & ChemPass?
- Higher success against tough targets.
- Less redundancy for easy targets.
- Superior pharmacophore analysis – better coverage, higher hit rates, fewer redundant compounds.
- Optimized fragment growth – improved hit rates and optimizability.
- More efficient vector analysis – fewer compounds, faster drug discovery.
- Short synthesis timelines, low costs, and high laboratory success rates.
